Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib plus Sorafenib in unresectable hepatocellular carcinoma
2008-001401-42Phase 2Terminated
- Sponsor
- Medical University of Vienna
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in hepatocellular carcinoma (HCC) comparing Erlotinib + Sorafenib with Sorafenib + placebo (2 arms). Primary endpoints: Time to progression and Safety. Started Jun 2008; status: terminated.
02
Drugs
erlotinibsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2008-001401-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001401-42.